Global ETF Survey 2026: Answer now →
Help us improve your experience. Please confirm your investor type:
Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

4.25% | +14.66% | +28.57% | +€10M | +€22M | €171M | 0.47% | ||
iShares Genomics Immunology and Healthcare Index ETF - CAD This ETF provides exposure to Equities | 4.25% | +18.01% | +33.44% | €0 | +€690K | €5.4M | 0.44% | |
First Trust NYSE Arca Biotechnology Index Fund ETF - USD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 3.44% | +12.43% | +20.36% | -€65M | +€908M | €2.45B | 0.54% | |
First Trust NYSE Arca Biotechnology ETF - CAD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 3.44% | +15.21% | +23.93% | +€529K | +€1.9M | €3.6M | 0.71% | Not rated |
First Trust NYSE Arca Biotechnology UCITS ETF - Acc - USD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 3.42% | +13.01% | +20.93% | -€1.8M | -€2.8M | €11M | 0.6% | |
AAM Sawgrass US Large Cap Quality Growth ETF - USD This ETF provides exposure to Other Large Cap US Equities | 3.34% | -0.50% | +8.53% | €0 | +€404K | €2.5M | 0.49% | Not rated |
Invesco Dynamic Biotechnology & Genome ETF - USD This ETF provides exposure to Equally Weighted US Equities | 3.07% | +9.66% | +10.58% | -€46M | -€2.1M | €245M | 0.58% | |
2.75% | +9.80% | +17.42% | -€667K | +€40M | €166M | 0.99% | Not rated | |
First Trust Health Care AlphaDEX Fund ETF - USD This ETF provides exposure to Other Large Cap US Health Care Equities | 2.50% | +6.91% | +7.82% | +€26M | -€37M | €843M | 0.61% | |
First Trust AlphaDEX U.S. Health Care Sector Index ETF - CAD Hedged This ETF provides exposure to Other Large Cap US Health Care Equities | 2.50% | +6.45% | +6.36% | €0 | €0 | €2M | 0.76% | Not rated |
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about Trackinsight